Timing of Antiretroviral Therapy for HIV in the Setting of TB Treatment
The convergent human immunodeficiency virus (HIV) and tuberculosis (TB) pandemics continue to collectively exact significant morbidity and mortality worldwide. Highly active antiretroviral therapy (HAART) has been a critical component in combating the scourge of these two conditions as both a preem...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2011/103917 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554182142328832 |
|---|---|
| author | Damani A. Piggott Petros C. Karakousis |
| author_facet | Damani A. Piggott Petros C. Karakousis |
| author_sort | Damani A. Piggott |
| collection | DOAJ |
| description | The convergent human immunodeficiency virus (HIV) and tuberculosis (TB) pandemics continue to collectively exact significant morbidity and mortality worldwide. Highly active antiretroviral therapy (HAART) has been a critical component in combating the scourge of these two conditions as both a preemptive and therapeutic modality. However, concomitant administration of antiretroviral and antituberculous therapies poses significant challenges, including cumulative drug toxicities, drug-drug interactions, high pill burden, and the immune reconstitution inflammatory syndrome (IRIS), thus complicating the management of coinfected individuals. This paper will review data from recent studies regarding the optimal timing of HAART initiation relative to TB treatment, with the ultimate goal of improving coinfection-related morbidity and mortality while mitigating toxicity resulting from concurrent treatment of both infections. |
| format | Article |
| id | doaj-art-d46e230eb3bc43f89c0cea2f6def21d3 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-d46e230eb3bc43f89c0cea2f6def21d32025-02-03T05:52:15ZengWileyClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/103917103917Timing of Antiretroviral Therapy for HIV in the Setting of TB TreatmentDamani A. Piggott0Petros C. Karakousis1Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, 1550 Orleans Street, Rm 110, Baltimore, MD 21231, USADivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, 1550 Orleans Street, Rm 110, Baltimore, MD 21231, USAThe convergent human immunodeficiency virus (HIV) and tuberculosis (TB) pandemics continue to collectively exact significant morbidity and mortality worldwide. Highly active antiretroviral therapy (HAART) has been a critical component in combating the scourge of these two conditions as both a preemptive and therapeutic modality. However, concomitant administration of antiretroviral and antituberculous therapies poses significant challenges, including cumulative drug toxicities, drug-drug interactions, high pill burden, and the immune reconstitution inflammatory syndrome (IRIS), thus complicating the management of coinfected individuals. This paper will review data from recent studies regarding the optimal timing of HAART initiation relative to TB treatment, with the ultimate goal of improving coinfection-related morbidity and mortality while mitigating toxicity resulting from concurrent treatment of both infections.http://dx.doi.org/10.1155/2011/103917 |
| spellingShingle | Damani A. Piggott Petros C. Karakousis Timing of Antiretroviral Therapy for HIV in the Setting of TB Treatment Clinical and Developmental Immunology |
| title | Timing of Antiretroviral Therapy for HIV in the Setting of TB Treatment |
| title_full | Timing of Antiretroviral Therapy for HIV in the Setting of TB Treatment |
| title_fullStr | Timing of Antiretroviral Therapy for HIV in the Setting of TB Treatment |
| title_full_unstemmed | Timing of Antiretroviral Therapy for HIV in the Setting of TB Treatment |
| title_short | Timing of Antiretroviral Therapy for HIV in the Setting of TB Treatment |
| title_sort | timing of antiretroviral therapy for hiv in the setting of tb treatment |
| url | http://dx.doi.org/10.1155/2011/103917 |
| work_keys_str_mv | AT damaniapiggott timingofantiretroviraltherapyforhivinthesettingoftbtreatment AT petrosckarakousis timingofantiretroviraltherapyforhivinthesettingoftbtreatment |